Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma

Paul Nghiem, Shailender Bhatia, Evan J. Lipson, William H. Sharfman, Ragini R. Kudchadkar, Andrew S. Brohl, Philip A. Friedlander, Adil Daud, Harriet M. Kluger, Sunil A. Reddy, Brian C. Boulmay, Adam Riker, Melissa A. Burgess, Brent A. Hanks, Thomas Olencki, Kari Kendra, Candice Church, Tomoko Akaike, Nirasha Ramchurren, Michi M. ShinoharaBob Salim, Janis M. Taube, Erin Jensen, Mizuho Kalabis, Steven P. Fling, Blanca Homet Moreno, Elad Sharon, Martin A. Cheever, Suzanne L. Topalian

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma'. Together they form a unique fingerprint.

Medicine & Life Sciences